Aspirin-Exacerbated Respiratory Disease in a Pediatric Patient Treated with Mepolizumab

Sánchez, Alejandra Méndez; Martínez, Jose Ramón Gutiérrez; Pelaz, Alejandro; Piñera, Maria Antonia Vázquez

doi:10.1016/j.arbr.2018.04.015

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mepolizumab has been shown to be efficacious in AERD in a retrospective subgroup analysis 25 and in case reports. 26,27 Omalizumab has been shown to decrease aspirin-induced bronchospasm in patients with AERD undergoing aspirin desensitization 28 and to improve CRSwNP symptoms in case reports. 29,30 In post hoc analyses, reslizumab improves symptoms of self-reported CRSwNP with and without aspirin sensitivity in patients with eosinophilic asthma.…”

Section: Discussionmentioning

confidence: 99%

Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease

Mustafa

Vadamalai

Scott

et al. 2020

Am J Rhinol�Allergy

View full text Add to dashboard Cite

Background Aspirin-exacerbated respiratory disease (AERD) affects 7% of asthmatics. Usual therapies are inadequate for asthma and/or nasal polyposis, leading to decreased quality of life. Objective Our objective was to evaluate the efficacy of dupilumab in AERD patients with uncontrolled, chronic rhinosinusitis with nasal polyposis (CRSwNP). Methods Patients 18 years and older with a physician diagnosis of AERD and sino-nasal outcome test 22 (SNOT 22) score ≥19 despite standard medical therapy were eligible for the study. Patients received one month of placebo dosing, followed by 6 months of dupilumab. Patients were blinded to the order of therapy. Wilcoxon-paired rank sum test was used to compare study outcomes at baseline and the completion of the study. Results Ten patients completed the study. The median baseline SNOT 22 score improved from 46 [IQR: 34 to 64.8] to 9.5 [IQR: 2.5 to 19] after 6 months of therapy (p = 0.0050). The median baseline Lund MacKay score improved from 21.5 [IQR: 17 to 23.3] to 4 [IQR: 1.2 to 6] after 6 months of therapy (p = 0.0050). There was also improvement in the following secondary outcomes: asthma control test (ACT), mini asthma quality of life questionnaire (AQLQ), and University of Pennsylvania Smell Identification test (UPSIT). Exhaled nitric oxide (FeNO), total serum IgE, 24-hour urinary leukotriene E4, and serum thymus and activation regulated cytokine (TARC) also decreased. There were no significant study-related adverse events. Conclusion Dupilumab was highly effective as add-on therapy for CRSwNP in AERD, improving patient-reported outcomes, sinus opacification, and markers of T2 inflammation.

show abstract

Section: Discussionmentioning

confidence: 99%

Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease

Mustafa

Vadamalai

Scott

et al. 2020

Am J Rhinol�Allergy

View full text Add to dashboard Cite

show abstract

“…In case of severe manifestations, biological therapies are required. In Supplementary Table S2 we mention a case report by Méndez Sánchez et al [ 58 ] in which a child of 12 years benefited from the use of mepolizumab.…”

Section: Resultsmentioning

confidence: 99%

“…The following are available online at , Table S1: Summary of the paediatric case reports on children treated with omalizumab [ 10 , 14 , 15 , 17 , 18 , 22 , 23 , 29 , 39 , 43 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 ], Table S2: Summary of the paediatric case reports on children treated with mepolizumab [ 53 , 54 , 58 , 59 ...…”

mentioning

confidence: 99%

An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics

2022

View full text Add to dashboard Cite

In recent years, off-label and unlicensed drug use has extensively developed in the paediatric population. For a long time, clinical trials in the paediatric population were considered complicated to perform because of ethical problems, causing frequent off-label use. Off-label drug use remains an important public health issue, especially for children with rare conditions or with diseases not responsive to conventional treatments. The present paper is a narrative review of the literature of off-label drug use in children. The aim of our study is to summarize the main works dealing with the off-label use of biological drugs in paediatrics. Further studies analyzing their efficacy, safety, and cost–benefit ratios are needed to extend the use of biological therapies to the paediatric population.

show abstract

Aspirin/ibuprofen/mepolizumab

2019

Reactions Weekly

View full text Add to dashboard Cite

Aspirin-Exacerbated Respiratory Disease in a Pediatric Patient Treated with Mepolizumab

Cited by 4 publications

References 11 publications

Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease

Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease

An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics

Aspirin/ibuprofen/mepolizumab

Contact Info

Product

Resources

About